Novel Therapeutic for the Treatment of Epithelial Cancers

ID# 2016-4463

Application & Market Utility

Epithelial cancers are among the most commonly diagnosed forms of cancer in the U.S. and the market for these indications is expected to grow over the next 10 years. As demonstrated in initial studies, Lectin-1 has the potential to enter as a targeted oncology drug for epithelial cancers. In addition, current chemotherapy drugs for epithelial cancers have IC50 values in the nanomolar range. Lectin-1 reduced IC50 values against epithelial cancers suggests it has the potential to be competitive with current state of the art.

Generate PDF